Journals / Turkish Journal of Medical Sciences / 2019 / Cilt: 49 - Sayı: 4

Childhood atopic dermatitis: current developments, treatment approaches, and future expectations

Pages
963–984
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, advances in the understanding of the pathogenic mechanisms of the disease have led to the productionof new treatment options, while ongoing drug trials also have had promising results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder of childhood.
📊
Key Findings & Data:Underlying factors thatcontribute to AD are impaired epithelial barrier, alterations in the lipid composition of the skin, immunological imbalance includingincreased Th2/Th1 ratio, proinflammatory cytokines, decreased T regulatory cells, genetic mutations, and epigenetic alterations.
💡
Conclusion & Impact:However, advances in the understanding of the pathogenic mechanisms of the disease have led to the productionof new treatment options, while ongoing drug trials also have had promising results.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder of childhood. Underlying factors thatcontribute to AD are impaired epithelial barrier, alterations in the lipid composition of the skin, immunological imbalance includingincreased Th2/Th1 ratio, proinflammatory cytokines, decreased T regulatory cells, genetic mutations, and epigenetic alterations. Atopicdermatitis is a multifactorial disease with a particularly complicated pathophysiology. Discoveries to date may be considered the tip ofthe iceberg, and the increasing number of studies in this field indicate that there are many points to be elucidated in AD pathophysiology.In this review, we aimed to illustrate the current understanding of the underlying pathogenic mechanisms in AD, to evaluate availabletreatment options with a focus on recently discovered therapeutic agents, and to determine the personal, familial, and economic burdensof the disease, which are frequently neglected issues in AD. Currently available therapies only provide transient solutions and cannotfully cure the disease. However, advances in the understanding of the pathogenic mechanisms of the disease have led to the productionof new treatment options, while ongoing drug trials also have had promising results.

🔖

Cite This Article

ŞAHİNER, Ü. M., ÇETİNKAYA, P. G. (2022). Childhood atopic dermatitis: current developments, treatment approaches, and future expectations. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 4, 963–984. https://ajindex.com/articles/610118

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. Journal of Allergy and Clinical Immunology 1999; 103: 125-138
  2. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. Is eczema really on the increase worldwide? Journal of Allergy and Clinical Immunology 2008; 121: 947-954
  3. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism 2015; 66: 8-16
  4. Huang E, Ong PY. Severe Atopic Dermatitis in Children. Current Allergy and Asthma Reports 2018; 18: 35-43
  5. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. Journal of Allergy and Clinical Immunology 2003; 112: 252-262
  6. Dharmage S, Lowe A, Matheson M, Burgess J, Allen K et al. Atopic dermatitis and the atopic march revisited. Allergy 2014; 69: 17-27
  7. Bieber T, Novak N. Pathogenesis of atopic dermatitis: new developments. Current Allergy and Asthma Reports 2009; 9: 291- 294
  8. D’Auria E, Banderali G, Barberi S, Gualandri L, Pietra B et al. Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target. Asian Pacific Journal of Allergy and Immunology 2016; 34: 98-108
  9. Mier P. Earliest description of the atopic syndrome? British Journal of Dermatology 1975; 92: 359
  10. Wise F, Sulzberger MB. Year Book of Dermatology and Syphilology. Chicago, IL, USA: Year Book Publishers 1933: 38-39
  11. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy and Clinical Immunology 2009; 124: 1251-1258
  12. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergologia et Immunopathologia 2013; 41: 73-85
  13. Civelek E, Sahiner U, Yüksel H, Boz A, Orhan F et al. Prevalence, burden, and risk factors of atopic eczema in schoolchildren aged 10–11 years: a national multicenter study. Journal of Investigational Allergology and Clinical Immunology 2011; 21: 270-277
  14. DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy & Asthma Proceedings 2012; 33: 227-234
  15. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunology and Allergy Clinics of North America 2010; 30: 269-280
  16. Tada J. Diagnostic standard for atopic de